On December 1, 2025 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, reported the acceptance of an abstract for poster spotlight (with oral) presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), being held on December 9-12, 2025, in San Antonio, TX.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Spotlight Presentation:

Title Rhenium (186Re) obisbemeda (rhenium nanoliposome, 186RNL) for the treatment of leptomeningeal metastases (LM): Phase 1 dose escalation study results

Presenter Andrew Brenner, M.D., Ph.D., Professor and Kolitz / Zachry Endowed Chair Neuro-Oncology Research; Co-Leader, Experimental and Developmental Therapeutics Program, University of Texas Health, Science Center at San Antonio

Presentation
Date/Time Friday, December 12, 2025, 7:39am to 7:42 am CST

Session
Date/Time Friday, December 12, 2025, 7:00am to 8:30 am CST

Location
Hemisfair 3, Henry B. Gonzalez Convention Center

About LM
Leptomeningeal metastases (LM) are a rare but severe complication of advanced cancer, affecting the fluid-lined structures of the central nervous system. LM occurs in approximately 5% of patients with metastatic cancer, with breast cancer, lung cancer, and melanoma being the most common sources. Median survival is typically 2-6 months, and effective treatment options are limited, highlighting the urgent need for novel therapies.

About REYOBIQ (rhenium Re186 obisbemeda)
REYOBIQ (rhenium Re186 obisbemeda) is a novel injectable radiotherapy specifically formulated to deliver direct targeted high dose radiation in CNS tumors in a safe, effective, and convenient manner to optimize patient outcomes. REYOBIQ has the potential to reduce off target risks and improve outcomes for CNS cancer patients, versus currently approved therapies, with a more targeted and potent radiation dose. Rhenium-186 is an ideal radioisotope for CNS therapeutic applications due to its short half-life, beta energy for destroying cancerous tissue, and gamma energy for real-time imaging. REYOBIQ is being evaluated for the treatment of recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancer in the ReSPECT-GBM, ReSPECT-LM, and ReSPECT-PBC clinical trials. ReSPECT-GBM is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), and ReSPECT-LM is funded by a three-year $17.6M grant by the Cancer Prevention & Research Institute of Texas (CPRIT). The Company’s ReSPECT-PBC clinical trial for pediatric brain cancer is supported by a $3 million grant from the U.S. Department of Defense’s Peer Reviewed Cancer Research Program.

(Press release, Plus Therapeutics, DEC 1, 2025, View Source [SID1234661025])

On December 1, 2025 Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, reported that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025, at 11:15 a.m. ET.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the fireside chat will be available in the Investor section of the Company’s website at www.syndax.com, where a replay will also be available for a limited time.

(Press release, Syndax, DEC 1, 2025, View Source [SID1234661024])

On December 1, 2025 Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, reported that it will host a conference call and live webcast at 8:30 am ET on Wednesday, December 3, 2025, to review new data from an interim analysis of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in BCG-Naïve patients with non-muscle invasive bladder cancer (NMIBC). The data will be featured during a poster session at the 26th Annual Meeting of the Society of Urologic Oncology (SUO). The Company will also provide an update on feedback from the U.S. Food and Drug Administration on a registrational path forward for TARA-002 in BCG-Naïve patients.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live event and accompanying slides can be accessed by visiting View Source or via the Events and Presentations section of the Company’s website: View Source A replay of the webcast will be archived for a limited time following the event.

(Press release, Protara Therapeutics, DEC 1, 2025, https://ir.protaratx.com/news-releases/news-release-details/protara-therapeutics-host-conference-call-and-webcast-review-1 [SID1234661023])

On December 1, 2025 Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company developing novel treatments for recurrent and metastatic cancer, reported that it has submitted a request for a foreign filing license from Spain for two provisional patents detailing new methods to treat resistant cancer and fibrosis. The patents will be filed with IP Australia under Propanc Pty Ltd, the Company’s wholly owned operating subsidiary based in Melbourne, Australia. These discoveries stem from Propanc’s Joint Research and Drug Discovery program with the Universities of Jaén and Granada in Spain and are expected to be filed subsequently in key global jurisdictions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first provisional patent covers methods for treating cancers that have developed resistance to chemotherapy and/or radiotherapy. Despite advancements in cancer therapies, global mortality rates remain high, and strategies to prevent recurrence are urgently needed. Treatment failure frequently occurs due to the emergence of multiple malignancies and resistance to standard therapies, underscoring the need for novel approaches.

The second provisional patent relates to compositions, methods, uses, and kits for the treatment of fibrosis, particularly organ fibrosis. Fibrosis is characterized by the excessive accumulation of scar tissue due to over-deposition of extracellular matrix (ECM) components, leading to stiffening, loss of function, and structural disruption of affected tissues. This maladaptive response can result from chronic injury or persistent inflammation and can impact nearly any organ system, including the lungs, liver, kidneys, and heart—contributing significantly to morbidity and mortality. Causes may include chronic inflammation, autoimmune and allergic responses, chemical insults, radiation, and tissue damage. For example, life expectancy following myocardial infarction-related scarring ranges from 3 to 8 years (ages 65–74), and for lung fibrosis patients is typically 3 to 5 years.

This fibrosis-related patent represents a world-first in Propanc’s intellectual property portfolio by describing the use of the Company’s lead product candidate, PRP—its proenzyme therapy—for chronic diseases beyond cancer. The biological pathways modulated by PRP to alter cancer cell behavior may also be applicable to conditions such as fibrosis. In particular, the epithelial-to-mesenchymal transition (EMT), a biological process central to embryogenesis and wound healing, plays a critical role in both tumor progression and tissue repair, making it a promising therapeutic target.

"The submission of these two patents represents a significant turning point for Propanc and the commercial potential of PRP for treating chronic diseases such as cancer and fibrosis," said James Nathanielsz, Propanc’s Chief Executive Officer. "Our planned Phase 1b, First-In-Human study in 2026 will define the target therapeutic dose of PRP, enabling us to explore this unique proenzyme therapy across multiple disease conditions in Phase 2 proof-of-concept studies. This work will be instrumental in establishing PRP as a novel therapeutic approach that encourages cells to differentiate toward normal behavior—without the cytotoxic effects associated with many standard treatments. We are tremendously excited by these developments."

(Press release, Propanc, DEC 1, 2025, View Source [SID1234661022])

On December 1, 2025 ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, reported a poster presentation highlighting data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO (Free ESMO Whitepaper) Asia Congress 2025 taking place December 5-7, 2025 in Singapore. The poster will focus on data in previously treated patients with HER2 exon 20 mutant NSCLC.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster presentation details:

Title: Enozertinib (ORIC-114), a Highly Selective, Brain Penetrant
EGFR and HER2 Inhibitor, in Patients with HER2 Exon 20
Mutant NSCLC: Randomized Dose Optimization
Presentation Number: 981P
Session Type and Title: Poster Display session and cocktail
Session Date & Time: Friday, December 5, 2025; 5:15 – 6:15 p.m. SGT

Full abstracts are available for public viewing via the ESMO (Free ESMO Whitepaper) Asia Congress website.

Conference Call and Webcast Details
In conjunction with the ESMO (Free ESMO Whitepaper) Asia Congress, ORIC will host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. A live webcast and audio archive of the conference call will be available through the investor section of ORIC’s website at www.oricpharma.com. The webcast will be available for replay for 90 days following the presentation.

(Press release, ORIC Pharmaceuticals, DEC 1, 2025, View Source [SID1234661021])